Clonal repertoire diversification of a neutralizing cytomegalovirus glycoprotein B-specific antibody results in variants with diverse anti-viral properties

Molecular Immunology

Volumn 44, Issue 5, 2007, Pages 680-690

  Barrios, Yvelise ^a   Knör, Susanne ^b   Lantto, Johan ^a   Mach, Michael ^b   Ohlin, Mats ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Antibody; Cytomegalovirus; Phage display; Repertoire; Virus neutralization

Indexed keywords

GLYCOPROTEIN B; VIRUS ANTIBODY; VIRUS VACCINE;

ANTIBODY ISOLATION; ANTIBODY LIBRARY; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; CYTOMEGALOVIRUS; IMMUNE RESPONSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PRIORITY JOURNAL; SOMATIC MUTATION; TECHNOLOGY; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELLS, CULTURED; CLONING, MOLECULAR; CYTOMEGALOVIRUS; FIBROBLASTS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; VIRAL ENVELOPE PROTEINS;

CYTOMEGALOVIRUS;

EID: 33748781701     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2006.04.024     Document Type: Article

References (37)

1. Al-Lazikan B., Lesk A.M., and Chothia C. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 273 (1997) 927-948
2. Britt W.J., and Mach M. Human cytomegalovirus glycoproteins. Intervirology 39 (1997) 401-412
3. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., and Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5 (2004) 233-236
4. Chatterjee A., Harrison C.J., Britt W.J., and Bewtra C. Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs. J. Infect. Dis. 183 (2001) 1547-1553
5. Compton T. Receptors and immune sensors: the complex entry path of human cytomegalovirus. Trends Cell Biol. 14 (2004) 5-8
6. Fowler K.B., Stagno S., Pass R.F., Britt W.J., Boll T., and Alford C.A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 326 (1992) 663-667
7. Goade D.E., Bell R., Yamada T., Mertz G.J., and Jenison S. Locations of herpes simplex virus type 2 glycoprotein B epitopes recognized by human serum immunoglobulin G antibodies. J. Virol. 70 (1996) 2950-2956
8. Institute of Medicine. Executive summary. In: Stratton K.R., Durch J.S., and Lawrence R.S. (Eds). Vaccines for the 21st Century: A Tool for Decisionmaking (2001), National Academy Press, Washington, DC 1-9
9. Institute of Medicine. Cytomegalovirus. In: Stratton K.R., Durch J.S., and Lawrence R.S. (Eds). Vaccines for the 21st Century: A Tool for Decisionmaking (2001), National Academy Press, Washington, DC 165-171
10. Jirholt P., Borrebaeck C.A.K., and Ohlin M. Antibody evolution in vitro from the centre to the periphery-applied to a human antibody fragment recognising the tumour-associated antigen mucin-1. J. Mol. Biol. 318 (2002) 407-416
11. Jirholt P., Ohlin M., Borrebaeck C.A.K., and Söderlind E. Exploiting sequence space: shuffling in vivo rearranged CDR into a master framework. Gene 215 (1998) 471-476
12. Kniess N., Mach M., Fay J., and Britt W.J. Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J. Virol. 65 (1991) 138-146
13. Kropff B., and Mach M. Identification of the gene coding for rhesus cytomegalovirus glycoprotein B and immunological analysis of the protein. J. Gen. Virol. 78 (1997) 1999-2007
14. Lantto J., Fletcher J.M., and Ohlin M. A divalent antibody format is required for neutralisation of human cytomegalovirus via antigenic domain 2 on glycoprotein B. J. Gen. Virol. 83 (2002) 2001-2005
15. Lantto J., Fletcher J.M., and Ohlin M. Binding characteristics determine the neutralizing potential of antibody fragments specific for antigenic domain 2 on glycoprotein B of human cytomegalovirus. Virology 305 (2003) 201-209
16. Lantto J., Jirholt P., Barrios Y., and Ohlin M. Chain shuffling to modify the properties of recombinant immunoglobulins. In: O'Brien P., and Aitken R. (Eds). Antibody Phage Display: Methods and Protocols (2001), Humana Press Inc., Totowa, NJ 303-316
17. ®. Nucleic Acids Res. 31 (2003) 307-310
18. MacCallum R.M., Martin A.C.R., and Thornton J.M. Antibody-antigen interactions: contact analysis and binding site topography. J. Mol. Biol. 262 (1996) 732-745
19. Michelson S. Human cytomegalovirus escape from immune detection. Intervirology 42 (1999) 301-307
20. Ohlin M., and Borrebaeck C.A.K. Insertions and deletions in hypervariable loops of antibody heavy chains contribute to molecular diversity. Mol. Immunol. 35 (1998) 233-238
21. Ohlin M., Owman H., Mach M., and Borrebaeck C.A.K. Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Mol. Immunol. 33 (1996) 47-56
22. Ohlin M., Owman H., Rioux J.D., Newkirk M.M., and Borrebaeck C.A.K. Restricted variable region gene usage and possible rheumatoid factor relationship among human monoclonal antibodies specific for the AD-1 epitope on cytomegalovirus glycoprotein B. Mol. Immunol. 31 (1994) 983-991
23. Ohlin M., Silvestri M., Sundqvist V.-A., and Borrebaeck C.A.K. Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques. Clin. Diagn. Lab. Immunol. 41 (1997) 07-111
24. Ohlin M., Sundqvist V.-A., Mach M., Wahren B., and Borrebaeck C.A.K. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB) studied by human monoclonal antibodies. J. Virol. 67 (1993) 703-710
25. Ørum H., Andersen P.S., Oster A., Johansen L.K., Riise E., Bjørnvad M., Svendsen I., and Engberg J. Efficient method for constructing comprehensive murine Fab antibody libraries displayed on phage. Nucleic Acids Res. 21 (1993) 4491-4498
26. Pantophlet R., and Burton D.R. Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies. Trends Mol. Med. 9 (2003) 468-473
27. Parren P.W., Gauduin M.C., Koup R.A., Poignard P., Fisicaro P., Burton D.R., and Sattentau Q.J. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol. Lett. 57 (1997) 105-112
28. Pass R.F., Duliege A.M., Boppana S., Sekulovich R., Percell S., Britt W., and Burke R.L. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J. Infect. Dis. 180 (1999) 970-975
29. Plotkin S. Is there a formula for an effective CMV vaccine?. J. Clin. Virol. 25 (2002) 13-21
30. Schoppel K., Haßfurther E., Britt W., Ohlin M., Borrebaeck C.A.K., and Mach M. Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Virology 216 (1996) 133-145
31. Snydman D.R., Werner B.G., Meissner H.C., Cheeseman S.H., Schwab J., Bednarek F., Kennedy Jr. J.L., Herschel M., Magno A., Levin M.J., Valaes T., Berkman E., Mciver J., Leszczynski J., Griffith J., and Grady G.F. Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. Pediatr. Infect. Dis. J. 14 (1995) 34-40
32. Spaete R.R. A recombinant subunit vaccine approach to HCMV vaccine development. Transplant. Proc. 23 (1991) 90-96
33. Speckner A., Glykofrydes D., Ohlin M., and Mach M. The antigenic domain 1 of human cytomegalovirus glycoprotein B forms an intramolecular disulphide bond and contains a multitude of discontinous epitopes. J. Gen. Virol. 80 (1999) 2183-2191
34. Speckner A., Kropff B., Knör S., and Mach M. The antigenic domain 1 of human cytomegalovirus glycoprotein B contains an intramolecular disulphide bond. J. Gen. Virol. 81 (2000) 2659-2663
35. Wilson P.C., de Bouteiller O., Liu Y.J., Potter K., Banchereau J., Capra J.D., and Pascual V. Somatic hypermutation introduces insertions and deletions into immunoglobulin V genes. J. Exp. Med. 187 (1998) 59-70
36. Xu J., Lyons P.A., Carter M.D., Booth T.W., Davis-Poynter N.J., Shellam G.R., and Scalzo A.A. Assessment of antigenicity and genetic variation of glycoprotein B of murine cytomegalovirus. J. Gen. Virol. 77 (1997) 49-59
37. Zaia J.A. Prevention and treatment of cytomegalovirus pneumonia in transplant recipients. Clin. Infect. Dis. 17 Suppl. 2 (1993) S392-S399